Active, not recruitingPhase 2NCT06717126
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Studying Uveal melanoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- iOnctura
- Principal Investigator
- Michael Lahn, MDiOnctura
- Intervention
- roginolisib(drug)
- Enrollment
- 85 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (16)
- SSD Tumori Rari e Melanoma Viale Orazio Flacco, Bari, Italy
- IRCSS National Cancer Institute, "G.Pascale" Foundation Dip. CORP-S di Ricerca ed Assistenziale Cute, Melanoma lmmunologia Oncologica Sperimentale e Terapie Innovative, Naples, Italy
- IRCSS Istituto Oncologico Veneto UOS Oncologia 2 del Melanoma Ospedale Busonera, Padua, Italy
- IRCCS Istituto Clinico Humanitas, Rozzano, Italy
- A.O.U.S. Santa Maria delle Scotte, Siena, Italy
- Institut Catala d'Oncologia - ICO L'Hospitalet, Barcelona, Spain
- Hospital Universitario La Paz, Madrid, Spain
- Complejo Hospitalario Universitario de Santiago - CHUS, Santiago de Compostela, Spain
- Hospital Universitario Virgen Macarena, University of Seville, Seville, Spain
- Consorcio Hospital General Universitario de València - CHGUV, Valencia, Spain
- East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre), Northwood, Middlesex, United Kingdom
- The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
- Beatson West of Scotland Cancer Centre, Glasgow (NHS Greater Glasgow & Clyde), Glasgow, United Kingdom
- University College London Hospital NHS, London, United Kingdom
- Royal Marsden Hospital, London, United Kingdom
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06717126 on ClinicalTrials.govOther trials for Uveal melanoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital
- RECRUITINGPHASE3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPHASE2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney
- RECRUITINGPHASE1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University